Why the study?
Metabolic abnormalities in type 2 diabetes increase the risk of cardiovascular disease and comorbidities, prompting comparison of tirzepatide and dulaglutide on these abnormalities.
Does tirzepatide reduce the prevalence of metabolic abnormalities compared to dulaglutide in Japanese patients with type 2 diabetes?
Does tirzepatide reduce the prevalence of metabolic abnormalities compared to dulaglutide in Japanese patients with type 2 diabetes?
Tirzepatide monotherapy is superior to dulaglutide in reducing metabolic abnormalities in Japanese patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Favors tirzepatide over dulaglutide for metabolic management in Japanese T2D; extends head-to-head RCT data on incretin therapies.
INTRODUCTION: The presence of metabolic abnormalities in patients with type 2 diabetes (T2D) increases the risk of cardiovascular disease and other comorbidities. This analysis compared the effects of tirzepatide (5, 10, and 15 mg) and dulaglutide 0.75 mg on the prevalence of metabolic abnormalities in Japanese patients with T2D. METHODS: ). RESULTS: subgroup (45.3%), with reductions observed across all BMI subgroups treated with tirzepatide. The proportion of participants with individual metabolic abnormalities showed similar trends to those observed for the composite endpoint. Tirzepatide was consistently superior to dulaglutide across all assessments. CONCLUSIONS: Tirzepatide reduced the prevalence of multiple metabolic abnormalities, indicating tirzepatide may have metabolic benefit in Japanese patients with T2D. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03861052.
No takes yet. Share an insight, caveat, or question.
Onishi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: